Nephrotic syndrome, anti-PLA2R and membranous glomerulonephritis. Is the renal biopsy necessary?

Alvarado, Raúl; Enríquez, Ricardo; Muci, Tania; Sirvent, Ana Esther; Vera, Valle Lozano; Millán, Isabel; González, César

doi:10.1016/j.nefroe.2016.10.013

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, assessment of both circulating anti-PLA2R antibody and PLA2R in biopsy samples will facilitate better categorization of patients with prognostic and therapeutic implications. Immunostaining by other newly discovered autoantibodies like thrombospondin type 1 domain-containing 7A (THSD7A) may help further characterize the heterogeneous nature of membranous nephropathy [22][23][24] Limitations of The Study The study was limited by heterogeneous population within the groups of secondary MN and non-membranous etiologies. Besides, evenly matched biopsy and serological numbers may have provided optimal results.…”

Section: Performance Of Pla2r As Diagnostic Toolmentioning

confidence: 99%

Anti-Phospholipase A2 Receptor Antibodies as Diagnostic Modality in Primary Idiopathic Membranous Nephropathy

Rath

Badwal

Tewari

et al. 2018

APALM

View full text Add to dashboard Cite

Background: Phospholipase A2 receptor (PLA2R), an IgG4 subclass antibody, is being extensively studied for diagnosis, monitoring and prognostication of cases of primary membranous nephropathy (MN). There is significant heterogeneity within the studies with most of the work targeted towards circulating PLA2R antibody. The present study evaluates PLA2R glomerular staining in primary MN as a diagnostic test in conjunction with the serology.Methods: Diagnostic study. We studied paraffin-embedded kidney biopsies of 60 patients with biopsy-proven MN, for the presence of PLA2R in glomerular immune deposits utilising immunohistochemistry. 60 cases of non MN cases along with autopsy renal tissue were used as controls. A subset of patients (n=40) were tested for circulating PLA2R antibody using quantitative sandwich enzyme immunoassay.Results: Positive PLA2R expression was present in 37/39 (94.8%) cases of primary MN, 5/21 (23.8% ) of secondary MN and 4/60 (6.6%) of non MN group. The expression was detected along glomerular basement membrane in granular pattern of varying intensities. Circulating anti-PLA2R antibodies were detected in 71.42% of primary MN cases, 8.3% of secondary MN cases and non MN group. PLA2R immunostaining exhibited higher sensitivity and modest specificity for differentiating primary from secondary MN (ROC-AUC :0.885 of IHC vs ROC-AUC: 0.776 of serology). The immunostaining however required precision and expertise to read the results. Conclusion:Tissue staining of PLA2R antibody in renal biopsies will be complementary to serology and two done in conjunction will be better discriminator between primary and secondary MN

show abstract

Section: Performance Of Pla2r As Diagnostic Toolmentioning

confidence: 99%